LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 25, 2016

Primary Completion Date

August 6, 2017

Study Completion Date

August 31, 2017

Conditions
Hemophilia
Interventions
BIOLOGICAL

Coagulation Factor VIIa (Recombinant)

LR769

Trial Locations (9)

2193

Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care, Parktown

46026

University and Polytechnic Hospital La Fe, Hemostasis and Thrombosis Unit, Valencia

64460

Dr. Jose Eleuterio Gonzalez Monterrey University Hospital, Monterrey

75235

UT Southwestern Medical Center, Dallas

125167

Hematology Research Center of the Russian Academy of Medical Sciences, Moscow

Unknown

Worthwhile Clinical Trials, Lakeview Hospital, Benoni

City Scientific-Practical center for diagnosics, Kiev

National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology, Kyiv

Institute of Blood Pathology and Transfusion Medicine, Lviv

All Listed Sponsors
collaborator

LFB USA, Inc.

INDUSTRY

lead

Laboratoire français de Fractionnement et de Biotechnologies

INDUSTRY

NCT02548143 - LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures | Biotech Hunter | Biotech Hunter